NASDAQ:NRSN
NeuroSense Therapeutics Ltd. Stock Company Profile
$1.21
-0.0100 (-0.82%)
At Close: May 17, 2024
Information
Building B, 11 HaMenofim Street
Herzliya 4672562
972 9 799 6183
www.neurosense-tx.com
Industry: Biotechnology
Sector: Healthcare
Description
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
